Bromodomain inhibitors constitute a category of medications designed to target BET (bromodomain and extra-terminal) proteins, disrupting their capacity to bind to acetylated lysines. This interference hinders transcriptional initiation and elongation. BET proteins play a role in regulating numerous genes associated with cell growth, apoptosis, and inflammation.